PRPO: Precipio, Inc.
About
Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.
Current Value
$6.001 Year Return
Current Value
$6.001 Year Return
Key Details
Market Cap
$9.10M
P/E Ratio
-2.98
1Y Stock Return
-13.65%
1Y Revenue Growth
31.31%
Dividend Yield
0.00%
Price to Book
0.8
Strategies that include PRPO
Stock's related to PRPO
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ABBV | 21.16% | $294.35B | +20.07% | 3.72% |
| JNJ | 20.46% | $368.37B | +1.24% | 3.18% |
| MNR | 20.33% | $1.66B | -10.71% | 15.90% |
| CPB | 17.16% | $12.96B | +7.08% | 3.40% |
| CB | 16.77% | $114.43B | +26.00% | 1.24% |
| VMI | 16.67% | $6.80B | +61.98% | 0.71% |
| ZI | 16.54% | $3.40B | -28.47% | 0.00% |
| RBRK | 16.23% | $8.03B | +38.16% | 0.00% |
| VFC | 16.21% | $7.51B | +16.70% | 1.89% |
| WRB | 15.36% | $22.94B | +29.98% | 0.69% |
| SPTN | 15.27% | $615.01M | -17.44% | 4.80% |
| FCNCA | 15.05% | $31.02B | +54.47% | 0.30% |
| ING | 14.98% | $49.95B | +13.75% | 7.61% |
| BMY | 14.83% | $118.10B | +20.11% | 4.09% |
| BNTX | 14.32% | $25.51B | +9.51% | 0.00% |
| DE | 14.12% | $109.46B | +4.56% | 1.45% |
| FET | 13.75% | $182.04M | -34.05% | 0.00% |
| AGYS | 13.75% | $3.44B | +39.55% | 0.00% |
| LPRO | 13.70% | $738.78M | +2.65% | 0.00% |
| HIG | 13.35% | $33.87B | +51.09% | 1.60% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NMFC | -<0.01% | - | - | 11.01% |
| CNSL | <0.01% | $548.51M | +9.98% | 0.00% |
| O | -0.01% | $50.04B | +6.78% | 5.49% |
| CVNA | -0.01% | $32.05B | +699.97% | 0.00% |
| GRMN | -0.01% | $39.82B | +73.79% | 1.43% |
| ENS | -0.01% | $3.75B | +6.54% | 0.97% |
| DLTR | -0.01% | $13.95B | -44.11% | 0.00% |
| REXR | 0.01% | $9.55B | -8.36% | 3.81% |
| TRS | 0.01% | $1.06B | +9.03% | 0.61% |
| RNA | 0.02% | $5.16B | +638.05% | 0.00% |
| FA | 0.02% | $3.04B | +17.64% | 0.00% |
| FHI | -0.02% | $3.38B | +35.20% | 2.93% |
| GXO | -0.02% | $7.02B | +3.60% | 0.00% |
| TDY | -0.02% | $21.66B | +18.31% | 0.00% |
| VYX | 0.02% | $2.04B | -13.51% | 0.00% |
| EGHT | 0.02% | $351.48M | -7.88% | 0.00% |
| SGRY | 0.03% | $2.89B | -28.97% | 0.00% |
| LBRT | -0.03% | $2.84B | -12.59% | 1.61% |
| CMS | 0.04% | $20.49B | +20.66% | 3.01% |
| SNA | 0.04% | $18.63B | +29.06% | 2.09% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DLR | -20.81% | $62.12B | +37.49% | 2.63% |
| SNPS | -18.19% | $82.03B | -1.18% | 0.00% |
| CDNS | -17.75% | $82.18B | +10.81% | 0.00% |
| ADUS | -17.72% | $2.18B | +37.62% | 0.00% |
| OFIX | -17.11% | $715.75M | +67.38% | 0.00% |
| FIVE | -17.09% | $4.65B | -54.68% | 0.00% |
| VCEL | -16.97% | $2.76B | +55.60% | 0.00% |
| ET | -16.93% | $61.49B | +31.09% | 7.07% |
| KRO | -16.85% | $1.30B | +35.66% | 5.51% |
| PODD | -16.81% | $18.38B | +44.49% | 0.00% |
| STRL | -16.53% | $5.93B | +200.06% | 0.00% |
| RXST | -16.41% | $1.82B | +62.89% | 0.00% |
| VST | -16.32% | $52.69B | +349.00% | 0.56% |
| FSM | -16.30% | $1.51B | +32.33% | 0.00% |
| FTAI | -16.22% | $17.54B | +308.36% | 0.70% |
| ACAD | -16.19% | $2.70B | -27.80% | 0.00% |
| AMBA | -15.91% | $2.44B | +7.82% | 0.00% |
| LRCX | -15.90% | $90.29B | -0.80% | 11.86% |
| KLAC | -15.78% | $82.35B | +11.80% | 0.98% |
| AMKR | -15.77% | $6.26B | -6.38% | 1.25% |
ETF's related to PRPO
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| IHF | -0.01% | $703.90M | 0.4% |
| EEM | 0.01% | $17.51B | 0.7% |
| REGL | -0.02% | $1.65B | 0.4% |
| IWN | 0.02% | $13.17B | 0.24% |
| FEP | -0.02% | $196.56M | 0.8% |
| XSOE | -0.02% | $1.75B | 0.32% |
| DLN | 0.03% | $4.41B | 0.28% |
| VOE | 0.04% | $18.25B | 0.07% |
| CMDY | 0.04% | $279.14M | 0.28% |
| BOXX | 0.05% | $4.43B | 0.1949% |
| SDVY | 0.06% | $7.17B | 0.6% |
| GNR | 0.06% | $2.89B | 0.4% |
| PY | -0.07% | $78.15M | 0.15% |
| IJS | 0.07% | $7.37B | 0.18% |
| PBW | 0.07% | $301.18M | 0.65% |
| BBAX | 0.10% | $4.66B | 0.19% |
| TAIL | -0.11% | $67.98M | 0.59% |
| DFSI | -0.11% | $523.15M | 0.24% |
| MDYV | -0.11% | $3.25B | 0.15% |
| SMDV | 0.13% | $754.57M | 0.4% |
News
Yahoo
Precipio Inc (PRPO) reports significant milestones with increased revenues and reduced cash burn, while addressing challenges in product division profitability and investor education.
SeekingAlpha
Precipio, Inc. (NASDAQ:PRPO) Q3 2024 Earnings Conference Call November 18, 2024 5:00 PM ETCompany ParticipantsIlan Danieli - CEOConference Call...
Yahoo
Precipio ( NASDAQ:PRPO ) Third Quarter 2024 Results Key Financial Results Revenue: US$5.21m (up 15% from 3Q 2023). Net...
Yahoo
Conference Call to be held on November 18, 2024, at 5:00 PM EST NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2024 corporate update call on November 18th at 5:00 PM ET. The call will provide commentary on Precipio's Q3-2024 10-Q filed today, including financial highlights and analysis of the company's core businesses. The conference call may be accessed by calling 844-695-5519 (international callers
Yahoo
The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patientsNEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-mak
Yahoo
Management lays out rationale and impact to shareholders belowNEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the Company’s repricing of a portion of its employee stock options to ensure their effectiveness as a retention tool for valuable employees. Management is confident that the practical, strategic, and economic benefit to shareholders will ultimately be positive. Retaining valuable employees in an extremely c
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.